109 related articles for article (PubMed ID: 9531052)
1. Comparison of antiplatelet effects of two nitric oxide-donating agents, FR146801 and FK409.
Hirasawa Y; Kato Y; Fukuyama S; Ohno M; Nishino S; Kato M; Kita Y
Thromb Haemost; 1998 Mar; 79(3):620-4. PubMed ID: 9531052
[TBL] [Abstract][Full Text] [Related]
2. Oral biological activities of spontaneous nitric oxide releasers are accounted for by their nitric oxide-releasing rates and oral absorption manners.
Kita Y; Hirasawa Y; Fukuyama S; Ohkubo K; Kato Y; Takamatsu H; Ohno M; Nishino S; Kato M; Seki J
J Pharmacol Exp Ther; 1996 Feb; 276(2):421-5. PubMed ID: 8632305
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of spontaneous nitric oxide releasers, FK409 and its derivatives.
Fukuyama S; Hirasawa Y; Kato Y; Nishio M; Ohno M; Nishino S; Maeda K; Kato M; Kita Y
J Pharmacol Exp Ther; 1997 Jul; 282(1):236-42. PubMed ID: 9223559
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet activities of FK409, a new spontaneous NO releaser.
Kita Y; Hirasawa Y; Yoshida K; Maeda K
Br J Pharmacol; 1994 Oct; 113(2):385-8. PubMed ID: 7834188
[TBL] [Abstract][Full Text] [Related]
5. Comparison of hemodynamic effects of nitric oxide (NO) donors with different NO-releasing properties in rats.
Kita Y; Hirasawa Y; Kato Y; Ohkubo K; Ohno M; Nishino S; Kato M; Fukuyama S
J Cardiovasc Pharmacol; 1997 Aug; 30(2):223-8. PubMed ID: 9269950
[TBL] [Abstract][Full Text] [Related]
6. Comparison of antiplatelet effects of FK409, a spontaneous nitric oxide releaser, with those of TRK-100, a prostacyclin analogue.
Hirasawa Y; Nishio M; Maeda K; Yoshida K; Kita Y
Eur J Pharmacol; 1995 Jan; 272(1):39-43. PubMed ID: 7713147
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a unique dihydropyrimidinone, ethyl 4-(4'-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate, as an effective antithrombotic agent in a rat experimental model.
Priya N; Singh P; Bhatia S; Medhi B; Prasad AK; Parmar VS; Raj HG
J Pharm Pharmacol; 2011 Sep; 63(9):1175-85. PubMed ID: 21827490
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409.
Kita Y; Hirasawa Y; Maeda K; Nishio M; Yoshida K
Eur J Pharmacol; 1994 May; 257(1-2):123-30. PubMed ID: 8082692
[TBL] [Abstract][Full Text] [Related]
9. [Effects of 3-n-butylphthalide on thrombosis formation and platelet function in rats].
Xu HL; Feng YP
Yao Xue Xue Bao; 2001 May; 36(5):329-33. PubMed ID: 12584852
[TBL] [Abstract][Full Text] [Related]
10. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
11. The in vitro pulmonary vascular effects of FK409 (nitric oxide donor): a study in normotensive and pulmonary hypertensive rats.
Wanstall JC; Kaye JA; Gambino A
Br J Pharmacol; 1997 May; 121(2):280-6. PubMed ID: 9154338
[TBL] [Abstract][Full Text] [Related]
12. The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process.
Berkels R; Klaus W; Boller M; Rösen R
Thromb Haemost; 1994 Aug; 72(2):309-12. PubMed ID: 7831670
[TBL] [Abstract][Full Text] [Related]
13. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
14. Acceleration of nitric oxide (NO) release from FK409, a spontaneous NO releaser, in the presence of sulfhydryl-bearing compounds.
Fukuyama S; Hirasawa Y; Cox D; Koda S; Kita Y
Pharm Res; 1995 Dec; 12(12):1948-52. PubMed ID: 8786971
[TBL] [Abstract][Full Text] [Related]
15. FR144420, a novel, slow, nitric oxide-releasing agent.
Kita Y; Ohkubo K; Hirasawa Y; Katayama Y; Ohno M; Nishino S; Kato M; Yoshida K
Eur J Pharmacol; 1995 Mar; 275(2):125-30. PubMed ID: 7796846
[TBL] [Abstract][Full Text] [Related]
16. Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood.
González-Correa JA; Arrebola MM; Guerrero A; Muñoz-Marín J; Ruiz-Villafranca D; Sánchez de La Cuesta F; De La Cruz JP
Platelets; 2005; 16(3-4):171-9. PubMed ID: 16011961
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity.
Jin YR; Im JH; Park ES; Cho MR; Han XH; Lee JJ; Lim Y; Kim TJ; Yun YP
J Cardiovasc Pharmacol; 2008 Jan; 51(1):45-54. PubMed ID: 18209568
[TBL] [Abstract][Full Text] [Related]
18. The antiplatelet activity of Geiji-Bokryung-Hwan, Korean traditional formulation, is mediated through inhibition of phospholipase C and inhibition of TxB(2) synthetase activity.
Park WH; Kim KS; Kim KH; Kim DS; Kim CH
Int Immunopharmacol; 2003 Jul; 3(7):971-8. PubMed ID: 12810354
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of FK409, a spontaneous nitric oxide releaser, on ischemic acute renal failure in rats.
Matsumura Y; Nishiura M; Deguchi S; Hashimoto N; Ogawa T; Seo R
J Pharmacol Exp Ther; 1998 Dec; 287(3):1084-91. PubMed ID: 9864296
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship studies on chalcone derivatives: potent inhibition of platelet aggregation.
Ko HH; Hsieh HK; Liu CT; Lin HC; Teng CM; Lin CN
J Pharm Pharmacol; 2004 Oct; 56(10):1333-7. PubMed ID: 15482650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
